Select Page
Responsive Centered YouTube Video
Research findings on clotting pathologies in long Covid patients and potential biomarkers.
  • Research collaboration on inflammatory molecules and clotting proteins. 11:12

  • Focus on platelets and red blood cells interaction in long Covid. 12:29

  • Identification of novel inflammatory molecules affecting symptoms. 13:44

  • Role of platelet hyperactivation in pathological clotting in patients. 14:00

Insights on nutraceutical interventions for long-hauler patients and their positive impact on various health parameters.
  • Nutraceutical interventions showed significant improvement in lung function and reduction of abnormal findings in clinical trials. 18:00

  • Combination of natural molecules in nutraceutical form led to rebalancing of the organism and restoration of organ functions. 19:07

  • Clinical observations indicated reduction in symptoms like fatigue, hypoxia, sore throat, and myalgia with nutraceutical intervention. 21:36

  • Significant increase in bioavailability of nutraceuticals was achieved, leading to improved efficacy in balancing body parameters. 24:52

  • Nutraceutical intervention demonstrated safety with no adverse events reported during clinical trials. 27:22

Insights on challenges faced by long Covid patients in accessing medical help and treatments.
  • Patients struggle globally to access medical help for long Covid. 40:52

  • Challenges in receiving referrals and accessing long Covid clinics in the UK. 41:04

  • Difficulty in getting support from the medical community for long Covid treatments. 41:23

Insights on potential treatments for long Covid and the importance of early intervention.
  • Research on help apheresis and triple therapy shows promising results in treating long Covid patients. 48:49

  • Early intervention within 3-6 months of onset may prevent microclots and alleviate symptoms. 51:16

  • Persistent microclots can lead to long-term damage and autoantibody issues if left untreated. 54:03

Insights on diagnosing neurological damage post-COVID infection and the role of vagus nerve dysfunction.
  • Symptoms of neurological damage may not be detectable through common imaging tests; biochemical level damage is crucial. 1:06:43

  • Discussion on the limitations of imaging tests in detecting early neurological damage. 1:07:03

  • Lack of specific diagnostic tools for biochemical injuries in neurons. 1:07:03

  • Symptoms reported by patients should be investigated as they can indicate underlying issues. 1:07:15

  • Importance of trusting patient-reported symptoms in diagnosing neurological issues. 1:07:43

  • Biochemical injuries release chemicals that may be detected in blood if they cross into the venous system. 1:08:03

  • Exploration of biochemical markers released by injured cells as potential diagnostic indicators. 1:08:09

Insights on managing long Covid through mast cell activation and early treatment.
  • Mast cell activation syndrome may be exacerbated by acute Covid, leading to diverse symptoms. 1:13:58

  • Early and effective treatment of acute Covid is crucial to reduce the risk of long Covid. 1:16:06

  • Genetic condition of mast cell activation affects up to 17% of the population. 1:17:03

  • Symptoms of long Covid include hypertension, brain fog, anxiety, fatigue, and more. 1:18:37

  • Approach to managing long Covid involves addressing methylation, detoxification, inflammation, and more. 1:19:31

  • Patients are advised to follow a low histamine diet and use type 1 antihistamines. 1:20:05

Innovative approaches to diagnosing and treating chronic inflammatory diseases.
  • Differentiating between long Covid, ME/CFS, fibromyalgia, and post-vaccination symptoms is crucial. 1:20:17

  • Gradual medication approach: starting with loratadine, then adding fexofenadine, and finally mast cell stabilizers. 1:20:24

  • Consideration of probiotics for gut microbiome imbalance in patients with chronic inflammatory diseases. 1:21:59

  • Use of low dose naltrexone (LDN) for neurological symptoms like tingling pains. 1:23:10

  • Identification of similarities in cytokine profiles among ME/CFS, long Covid, and post-vaccination long haulers. 1:31:43

  • Treatment targeting CCR5/CCL5 pathways and fractalkine receptors to alleviate symptoms in long Covid and post-vaccination individuals. 1:32:00

  • Classification of chronic inflammatory diseases based on distinct cytokine nodes for tailored therapy. 1:33:23

  • Promising results of using maraviroc and statins in reducing symptom severity and correlating with biomarkers. 1:34:19

Insights on managing long COVID symptoms through biomarkers and treatment options.
  • Biomarkers like soluble CD40 ligand and VEGF show correlation with neurodisease and dysautonomia symptoms. 1:34:34

  • Treatment with Maravarak and statins leads to statistically significant decrease in symptoms like dysautonomia and fatigue. 1:34:41

  • Fatigue in long COVID patients correlates with TNF alpha and interleukin-2 levels. 1:35:14

  • Correlation between biomarkers and symptoms aids in understanding treatment response in long COVID. 1:35:55

  • Differentiating long COVID cases based on immune dysregulation and latent infections is crucial for tailored treatment. 1:39:05

  • Early recognition and treatment of mast cell activation syndrome can prevent prolonged symptoms in long COVID. 1:40:26

  • Low histamine diet may be necessary for managing MCAS symptoms, potentially long-term. 1:44:02

  • Resources like marcelaction.org and Dr. Tanya Dempsey’s website offer support and information on MCAS. 1:45:17

  • Collaboration between patients and doctors can improve recognition and management of MCAS in long COVID. 1:46:10

  • High immunoglobulin E levels may indicate mast cell activation in long COVID patients, requiring specific treatment approaches. 1:47:05

Insights on categorizing long Covid, importance of accurate testing, and challenges in understanding the complete disease picture.
  • Classification of long Covid into different categories is vital for accurate treatment interventions. 1:48:09

  • Differentiating between primary and secondary causes of pathology in long Covid is crucial. 1:48:21

  • Developing simple tests to categorize patients based on markers can improve treatment efficacy. 1:48:43

  • Challenges in interpreting serology for chronic viruses like EBV highlight the need for accurate categorization. 1:49:03

  • Debate on viral persistence versus viral debris in long Covid, emphasizing the importance of accurate understanding. 1:52:05

  • Focus on proteomics to uncover the role of proteins in autoimmune diseases and potential treatment avenues. 1:57:15

  • Investing in biomarkers for neurological damage in long Covid to understand and address the associated symptoms. 2:00:05

Insights on addressing stigma and advancing research on Long Covid.
  • Long Covid patients often have pre-existing gastrointestinal issues. 2:01:12

  • Research suggests Long Covid involves viral-mediated autoimmune responses. 2:01:19

  • Clotting issues in Long Covid patients may be linked to inflammatory molecules. 2:02:35

  • Patients with Long Covid may benefit from targeting microclots for diagnostics and treatment. 2:03:58

  • Identifying specific molecular origins of symptoms in Long Covid is crucial for effective treatment. 2:04:05

  • Classification of Long Covid subtypes is essential for tailored treatment strategies. 2:08:01

  • Addressing stigma around Long Covid requires accurate reporting in media and scientific validation. 2:12:30

  • Good science and proper media coverage can help change perceptions of Long Covid. 2:12:48

  • Validation of Long Covid conditions through research can combat denial and stigma. 2:13:13

  • Funding challenges may hinder research efforts in understanding and treating Long Covid. 2:13:24

Insights from experts on addressing challenges in understanding and treating Long Covid
  • Long Covid lacks clear protocols and medical acceptance, leading to psychologizing of patients. 2:13:45

  • Collaboration and research trials are crucial to develop effective treatments for Long Covid. 2:16:01

  • Chronic Fatigue Syndrome serves as a cautionary example of the consequences of not addressing root causes. 2:25:00

  • Focusing on treating causes rather than symptoms is essential in addressing complex conditions like Long Covid. 2:26:19

  • Comprehensive research into biomarkers, co-infections, and biological pathways is necessary for a deeper understanding of Long Covid. 2:28:41

Discussion on challenges and solutions for long Covid patients, emphasizing collaboration and media impact.
  • Collaboration among doctors and researchers is crucial for understanding and treating long Covid. 2:29:15

  • Nutraceutical interventions and research on epigenetic settings are explored for potential benefits. 2:29:26

  • Efforts to identify molecules for rebalancing the body and supporting conventional treatments are underway. 2:30:00

  • Challenges in medical fraternity highlighted, emphasizing the need for deeper disease understanding. 2:33:01

  • Media’s impact on patient support and research dissemination discussed, highlighting both positive and negative aspects. 2:37:14

  • Global collaboration for research and trials on long Covid encouraged among international peers. 2:40:38

  • Patient reluctance to discuss symptoms addressed, emphasizing the role of social media in connecting and supporting individuals. 2:41:47

Collaborative wrap-up of a congress discussing long-term solutions for post-Covid symptoms.
  • Emphasis on collaboration for future progres. 2:42:45

  • Acknowledgment of eye-opening discussio. 2:43:00

  • Hope for clearer answers in the futur. 2:43:15

  • Recognition of critical role in finding solution. 2:43:24

  • Encouragement for continued treatment developmen. 2:43:34